ZYUS Life Sciences Corp. is a Canadian-based life sciences company. The company is headquartered in Saskatoon, Saskatchewan. The company went IPO on 2000-10-18. Its lead research program is focused on developing a purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for the treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management. Both pre-clinical and non-clinical studies have been conducted on this formulation and patent applications have been filed.
Follow-Up Questions
ZLSCF の株価パフォーマンスは？
ZLSCF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
ZYUS Life Sciences Corp の主な事業テーマや業界は？
ZYUS Life Sciences Corp は Pharmaceuticals 業界、セクターは Health Care に属しています。
